🇺🇸 Filgrastim/pegfilgrastim in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 8

Most-reported reactions

1. Blindness — 1 report (12.5%)
2. Csf Protein Increased — 1 report (12.5%)
3. Csf Test Abnormal — 1 report (12.5%)
4. Malignant Nervous System Neoplasm — 1 report (12.5%)
5. Optic Nerve Disorder — 1 report (12.5%)
6. Pain In Extremity — 1 report (12.5%)
7. Papilloedema — 1 report (12.5%)
8. Recurrent Cancer — 1 report (12.5%)

Source database →

Frequently asked questions

Is Filgrastim/pegfilgrastim approved in United States?

Filgrastim/pegfilgrastim does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Filgrastim/pegfilgrastim in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.